|
Using patient-reported outcomes to assess the impact of germline genetic testing on prostate cancer patients. |
| |
|
|
Stock and Other Ownership Interests - Invitae |
Travel, Accommodations, Expenses - Invitae |
| |
|
|
Leadership - Alessa Therapeutics; Photocure |
Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer |
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow |
Expert Testimony - Ferring |
Other Relationship - Alessa Therapeutics; Photocure |
| |
|
Research Funding - Invitae |
| |
Christopher Michael Pieczonka |
Employment - Associated Medical Professionals of New York |
Leadership - Associated Medical Professionals of New York |
Stock and Other Ownership Interests - US Urology Partners |
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Janssen; Merck; Myovant Sciences; Pfizer/Astellas; Sun Pharma |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Merck; Pfizer/Astellas; Sun Pharma; Sun Pharma; Tolmar |
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Foundation Medicine; Janssen Oncology; Myovant Sciences; Pfizer; Sun Pharma |
Research Funding - Advantagene; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen Oncology; Merck; Pfizer |
| |
|
Research Funding - Invitae |
| |
|
Research Funding - Invitae |
| |
|
Consulting or Advisory Role - Bayer; Immuno bio; Marius Pharmaceuticals |
Research Funding - Invitae |
| |
|
Honoraria - AstraZeneca; Dendreon; Janssen Oncology; Myriad Genetics; Pfizer/Astellas |
Consulting or Advisory Role - BK Ultrasound |
Speakers' Bureau - Janssen Oncology; Myovant Sciences; Pfizer/Astellas |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - UROGPO |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Decipher Biosciences; Janssen Oncology; Myovant Sciences; Myriad Genetics; Pfizer/EMD Serono; Urogen pharma; UROGPO |
Speakers' Bureau - Astellas Medivation; AstraZeneca; Clovis Oncology; Janssen; Merck |
Research Funding - Astellas Pharma (Inst); AstraZeneca/Merck (Inst); Bayer (Inst); Clovis Oncology (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer/Astellas (Inst); Urogen pharma (Inst) |
| |
|
Research Funding - Invitae |
| |
|
Consulting or Advisory Role - Decipher Biosciences |
Research Funding - Invitae |
| |
|
Consulting or Advisory Role - Dendreon; Exact Imaging; Myovant Sciences |
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Exact Imaging; Janssen; Myovant Sciences; Pfizer |
Research Funding - Invitae |
| |
|
Research Funding - Invitae |
| |
|
Stock and Other Ownership Interests - Doximity |
|
Consulting or Advisory Role - Alphasights; Bayer; Foundation Medicine; Gerson Lehrman Group; Guidepoint Global; Janssen; LabCorp; Leap Therapeutics; Lilly; Myovant Sciences; Pfizer; Sanofi; silverlight |
Travel, Accommodations, Expenses - Pfizer |
| |
|
Stock and Other Ownership Interests - Juva Life |
Consulting or Advisory Role - Biofidelity; Invitae |
| |
|
|
Stock and Other Ownership Interests - InVitae |
| |
|
|
|
Stock and Other Ownership Interests - Genome Medical; Invitae; Maze Therapeutics |
|
Consulting or Advisory Role - Genome Medical; Maze Therapeutics; Pfizer |
Patents, Royalties, Other Intellectual Property - Royalties on a patented mouse model for Parkinson disease held by the National Institutes of Health and the University of California San Francisco |
| |
|
|
Stock and Other Ownership Interests - Invitae |
Consulting or Advisory Role - Taproot Health Inc |